Exclusive Video Marketing Software for Startups 

Novo Nordisk to Buy Corvidia Therapeutics, for Up To $2.1 Billion

Bagsværd, Denmark-based global healthcare company Novo Nordisk A/S (New York Stock Exchange: NVO) is to acquire Corvidia Therapeutics Inc., a Waltham, Massachusetts-based clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Corvidia Therapeutics for an upfront payment of 725 million US dollars in cash. Total payments to Corvidia Therapeutics shareholders could ultimately amount to 2.1 billion US dollars in cash upon the achievement of certain regulatory and sales milestones by Novo Nordisk. Led by Marc de Garidel, chief executive officer, Corvidia Therapeutics is advancing ziltivekimab, a fully human monoclonal antibody directed against Interleukin-6 (IL-6). Founded in 1923, Novo Nordisk is a global healthcare company which employs about 43,100 people in 80 countries and markets its products in around 170 countries.

Startup Around is now on Telegram and Whatsapp. For the best startup stories & resources, subscribe us on Telegram & Whatsapp.
World-class video marketing software for startups